Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
16.12
+0.03 (0.20%)
Nov 12, 2025, 2:25 PM EST - Market open
Amarin Corporation Revenue
Amarin Corporation had revenue of $49.67M in the quarter ending September 30, 2025, with 17.43% growth. This brings the company's revenue in the last twelve months to $226.73M, down -5.93% year-over-year. In the year 2024, Amarin Corporation had annual revenue of $228.61M, down -25.51%.
Revenue (ttm)
$226.73M
Revenue Growth
-5.93%
P/S Ratio
1.47
Revenue / Employee
$824,484
Employees
275
Market Cap
335.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 228.61M | -78.30M | -25.51% |
| Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
| Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
| Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
| Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AMRN News
- 2 days ago - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - GlobeNewsWire
- 9 days ago - Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 14 days ago - Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewsWire
- 6 weeks ago - Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom - Seeking Alpha
- 2 months ago - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 - GlobeNewsWire
- 2 months ago - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups - GlobeNewsWire
- 2 months ago - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 - GlobeNewsWire